Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. (Q40659303)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Johannes Waltenberger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Gershon Golomb

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Aviv Gazit

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Kevin Yee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Andrea Uecker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Frank-D Böhmer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Tobias Sjöblom

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Arne Ostman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Shmuel Banai

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Alexander Levitzki

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

Bioorganic & Medicinal Chemistry

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

2007-2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670652%20AND%20SRC:MED&resulttype=core&format=json

Protein tyrosine kinase inhibitors as novel therapeutic agents

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Substrate competitive inhibitors of IGF-1 receptor kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

PDGF alpha- and beta-receptors activate unique and common signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021

cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2803%2900048-8

7 January 2021